- Home
- NTLA vs WRLD Comparison
NTLA vs WRLD Comparison
Compare NTLA & WRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- WRLD
- Stock Information
- Founded
- NTLA 2014
- WRLD 1962
- Country
- NTLA United States
- WRLD United States
- Employees
- NTLA N/A
- WRLD N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- WRLD Finance: Consumer Services
- Sector
- NTLA Health Care
- WRLD Finance
- Exchange
- NTLA Nasdaq
- WRLD Nasdaq
- Market Cap
- NTLA 686.3M
- WRLD 656.7M
- IPO Year
- NTLA 2016
- WRLD 1991
- Fundamental
- Price
- NTLA $7.23
- WRLD $124.86
- Analyst Decision
- NTLA Buy
- WRLD
- Analyst Count
- NTLA 18
- WRLD 0
- Target Price
- NTLA $39.44
- WRLD N/A
- AVG Volume (30 Days)
- NTLA 3.8M
- WRLD 34.1K
- Earning Date
- NTLA 05-08-2025
- WRLD 05-01-2025
- Dividend Yield
- NTLA N/A
- WRLD N/A
- EPS Growth
- NTLA N/A
- WRLD 29.61
- EPS
- NTLA N/A
- WRLD 14.42
- Revenue
- NTLA $57,877,000.00
- WRLD $558,622,726.00
- Revenue This Year
- NTLA N/A
- WRLD N/A
- Revenue Next Year
- NTLA N/A
- WRLD $3.69
- P/E Ratio
- NTLA N/A
- WRLD $8.66
- Revenue Growth
- NTLA 59.55
- WRLD N/A
- 52 Week Low
- NTLA $5.90
- WRLD $101.85
- 52 Week High
- NTLA $28.18
- WRLD $161.63
- Technical
- Relative Strength Index (RSI)
- NTLA 43.76
- WRLD 50.84
- Support Level
- NTLA $6.73
- WRLD $120.99
- Resistance Level
- NTLA $7.76
- WRLD $124.26
- Average True Range (ATR)
- NTLA 0.71
- WRLD 7.14
- MACD
- NTLA 0.11
- WRLD 0.48
- Stochastic Oscillator
- NTLA 68.91
- WRLD 74.45
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.